Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|November 14, 2022
Generation and Integrated Analysis of Advanced Patient-Derived Orthoxenograft Models (PDOX) for the Rational Assessment of Targeted Therapies in Endometrial CancerLaura Devis-Jauregui, August Vidal, Laura Plata-Peña, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 16, 2020
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a <i>BRCA1</i> or <i>BRCA2</i> Gene AlterationWassim Abida, Akash Patnaik, David Campbell, et al.
The New England Journal of Medicine|February 16, 2023
Rucaparib or Physician's Choice in Metastatic Prostate CancerKarim Fizazi, Josep M Piulats, M Neil Reaume, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2021
Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 StudyAndrea Loehr, Akash Patnaik, David Campbell, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 15, 2020
Role of POLE and POLD1 in familial cancerPilar Mur, Sandra García-Mulero, Jesús Del Valle, et al.
The New England Journal of Medicine|September 22, 2021
Overall Survival Benefit with Tebentafusp in Metastatic Uveal MelanomaPaul Nathan, Jessica C Hassel, Piotr Rutkowski, et al.
European Urology|June 5, 2023
Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 StudyWassim Abida, David Campbell, Akash Patnaik, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2018
Orthoxenografts of Testicular Germ Cell Tumors Demonstrate Genomic Changes Associated with Cisplatin Resistance and Identify PDMP as a Resensitizing AgentJosep M Piulats, August Vidal, Francisco J García-Rodríguez, et al.
Pageof 7